Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?

Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?

Da: GRACEcast
0 0 5 anni fa
Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.

Seguici su Facebook